Article

Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism

Hebrew University-Hadassah Medical School
Pediatric Nephrology (impact factor: 2.52). 11/1994; 8(6):724-726. DOI:10.1007/BF00869102 pp.724-726

ABSTRACT Twelve dialysis patients received oral pulse therapy with 1--hydroxyvitamin D3 in a dose of 0.1 g/kg body weight twice weekly and daily calcium carbonate (1.5–3.5 g) for a period of 8–12 months. This treatment was very effective in suppressing secondary hyperparathyroidism without causing hypercalcaemia and/or hyperphosphataemia.

0 0
 · 
0 Bookmarks
 · 
17 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

0.1 g/kg body weight
 
hyperphosphataemia
 
oral pulse therapy
 
suppressing secondary hyperparathyroidism